Publication date context February 11 2026. A new randomized controlled trial named RAPHAel is testing robotic technologies to address apathy in dementia. The study evaluates a telepresence robotic system and a Pepper robot linked to a CAIR server, alongside an occupational therapy component. The trial is not yet recruiting and is sponsored by Giovanna Zamboni and institutions including the University of Genova, Fondazione Don Carlo Gnocchi Onlus, and the University of Florence. Regulators and device developers focusing on dementia care technologies will want to monitor this effort as it progresses. This article summarizes what is known from the ClinicalTrials.gov record and sponsor materials and notes how this aligns with regulatory expectations for medical devices used in vulnerable populations. The information appears on the ClinicalTrials.gov page with identifier NCT07404410 and is described as an investigation focused on apathy in dementia. For interested readers we include related content and links to regulatory coverage and technology context.
What is the RAPHAel trial and what does it seek to test?
The RAPHAel study is described as a randomized controlled trial addressing apathy in people living with dementia. The design aims to assess whether robotics and allied therapies can influence apathetic symptoms and related engagement in daily activities. The source text specifies three components for evaluation: a telepresence robotic system, a Pepper robot connected to a CAIR server, and a behavioral element described as occupational therapy. The sponsor list includes Giovanna Zamboni and three Italian institutions: the University of Genova, Fondazione Don Carlo Gnocchi Onlus, and the University of Florence. This combination signals an international collaboration on dementia care technologies. The not yet recruiting status indicates that participant enrollment has not begun at this time. Readers should watch for updates on the ClinicalTrials.gov page cited below and for any published results that may inform device safety and performance claims. For readers seeking additional context, related discussions can be found in our Regulatory Affairs coverage and in our technology focused posts linked here: Regulatory considerations for robotics in dementia trials and Technology overview of telepresence robots in dementia care.
How is the RAPHAel trial designed and what components are tested?
The interventions listed in the source text are a telepresence robotic system, a Pepper robot connected to a CAIR server, and a behavioral component described as occupational therapy. The report does not disclose details on randomization arms, sample size or primary endpoints. The enrollment status is Not yet recruiting. Sponsors include Giovanna Zamboni and the University of Genova, Fondazione Don Carlo Gnocchi Onlus, and the University of Florence. The combination of devices and therapy suggests a blended approach intended to address social engagement and functional activity in people with dementia, with safety considerations that regulators will want to monitor as results emerge. For readers needing more depth the ClinicalTrials.gov page provides the official description: ClinicalTrials.gov NCT07404410.
Telepresence and Pepper robot details
Telepresence robotics enable remote presence and interaction, which could address social engagement and stimulation for people living with dementia. The Pepper robot is described as connected to a CAIR server, suggesting an integrated framework for data exchange and remote control. The source text does not provide technical specifications or evidence from prior trials, so readers should await peer reviewed results to understand device reliability and user experience in clinical use.
What is the regulatory context and who may be affected?
From a regulatory perspective the study involves devices categorized as a telepresence system and a humanoid robot used in dementia care. The description of these interventions as investigational aligns with MDR Annex XIV expectations. Sponsors are identified with multiple Italian institutions providing oversight. The Not yet recruiting status means enrollment has not begun, and any future results will inform risk management postmarket considerations and potential use in care pathways if efficacy and safety are demonstrated. Regulators will evaluate adverse events reporting device reliability in daily care and alignment with the intended use as described by sponsors. Readers can refer to the official page for updates: ClinicalTrials.gov NCT07404410.
FAQ
- What is the RAPHAel trial and what does it test and why is it important for apathy in dementia?
- What interventions are tested The telepresence robotic system a Pepper robot connected to a CAIR server and an occupational therapy component are listed in the registry.
- Who funds the trial Sponsors include Giovanna Zamboni the University of Genova Fondazione Don Carlo Gnocchi Onlus and the University of Florence.
- What is the recruitment status The record states Not yet recruiting indicating enrollment has not begun.
- Where can I get more information The ClinicalTrials.gov entry for NCT07404410 has full details.
Conclusion
RAPHAel represents an early phase effort to combine robotics with therapy to address apathy in dementia. Regulators and device developers should monitor the trial for data on safety device performance user engagement and potential impact on care decisions as results become available.
Disclaimer This article is intended for professionals and is not legal advice. It reflects information currently available from the source and does not establish regulatory clearance status or final device approvals.
For full information about the announcement see the link below.
https://clinicaltrials.gov/study/NCT07404410?term=medical+device